Longterm Treatment with Endothelin Receptor Antagonist Bosentan and Iloprost Improves Fingertip Blood Perfusion in Systemic Sclerosis

REFERENCES

1. 1.↵
   1. Cutolo M,
   2. Sulli A,
   3. Smith V

   . Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol 2010;6:578–87.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Cutolo M,
   2. Ferrone C,
   3. Pizzorni C,
   4. Soldano S,
   5. Seriolo B,
   6. Sulli A

   . Peripheral blood perfusion correlates with microvascular abnormalities in systemic sclerosis: a laser-Doppler and nailfold videocapillaroscopy study. J Rheumatol 2010;37:1174–80.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Rosato E,
   2. Molinaro I,
   3. Borghese F,
   4. Rossi C,
   5. Pisarri S,
   6. Salsano F

   . Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension. J Rheumatol 2010;37:2531–9.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Herrick AL

   . Contemporary management of Raynaud’s phenomenon and digital ischaemic complications. Curr Opin Rheumatol 2011;23:555–61.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Sulli A,
   2. Ruaro B,
   3. Alessandri E,
   4. Pizzorni C,
   5. Cimmino MA,
   6. Zampogna G,
   7. et al.

   Correlations between nailfold microangiopathy severity, finger dermal thickness and fingertip blood perfusion in systemic sclerosis patients. Ann Rheum Dis 2014;73:247–51.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Caramaschi P,
   2. Canestrini S,
   3. Martinelli N,
   4. Volpe A,
   5. Pieropan S,
   6. Ferrari M,
   7. et al.

   Scleroderma patients nailfold videocapillaroscopic patterns are associated with disease subset and disease severity. Rheumatology 2007;46:1566–9.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Mubarak KK

   . A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med 2010;104:9–21.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Silver RM

   . Endothelin and scleroderma lung disease. Rheumatology 2008;47 Suppl 5:v25–6.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Cutolo M,
   2. Zampogna G,
   3. Vremis L,
   4. Smith V,
   5. Pizzorni C,
   6. Sulli A

   . Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis. J Rheumatol 2013;40:40–5.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Sulli A,
    2. Secchi ME,
    3. Pizzorni C,
    4. Cutolo M

    . Scoring the nailfold microvascular changes during the capillaroscopic analysis in systemic sclerosis patients. Ann Rheum Dis 2008;67:885–7.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Smith V,
    2. Pizzorni C,
    3. De Keyser F,
    4. Decuman S,
    5. Van Praet JT,
    6. Deschepper E,
    7. et al.

    Reliability of the quantitative and semiquantitative nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: a two-centre study. Ann Rheum Dis 2010;69:1092–6.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Smith V,
    2. De Keyser F,
    3. Pizzorni C,
    4. Van Praet JT,
    5. Decuman S,
    6. Sulli A,
    7. et al.

    A nailfold capillaroscopy for day-to-day clinical use: construction of a simple scoring modality as a clinical prognostic index for digital trophic lesions. Ann Rheum Dis 2011;70:180–3.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Steen V,
    2. Denton CP,
    3. Pope JE,
    4. Matucci-Cerinic M

    . Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology 2009;48:iii19–24.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Moore TL,
    2. Vail A,
    3. Herrick AL

    . Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud’s phenomenon. Rheumatology 2007;46:363–4.

    OpenUrlFREE Full Text
15. 15.↵
    1. Hettema ME,
    2. Zhang D,
    3. Stienstra Y,
    4. Smit AJ,
    5. Bootsma H,
    6. Kallenberg CG

    . No effects of bosentan on microvasculature in patients with limited cutaneous systemic sclerosis. Clin Rheumatol 2009;28:825–33.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Guiducci S,
    2. Bellando-Randone S,
    3. Bruni C,
    4. Carnesecchi G,
    5. Maresta A,
    6. Iannone F,
    7. et al.

    Bosentan fosters microvascular de-remodelling in systemic sclerosis. Clin Rheumatol 2012;31:1723–5.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Lambova SN,
    2. Müller-Ladner U

    . New lines in therapy of Raynaud’s phenomenon. Rheumatol Int 2009;29:355–63.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Sulli A,
    2. Ruaro B,
    3. Smith V,
    4. Pizzorni C,
    5. Zampogna G,
    6. Gallo M,
    7. et al.

    Progression of nailfold microvascular damage and antinuclear antibody pattern in systemic sclerosis. J Rheumatol 2013;40:634–9.

    OpenUrlAbstract/FREE Full Text